210 related articles for article (PubMed ID: 26512574)
1. A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Luo Z; Zhang X; Peng W; Wu X; Wang H; Yu H; Wang J; Chang J; Hong X
Medicine (Baltimore); 2015 Oct; 94(43):e1777. PubMed ID: 26512574
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Späth-Schwalbe E; Genvresse I; Koschuth A; Dietzmann A; Grunewald R; Possinger K
Anticancer Drugs; 2000 Jun; 11(5):325-9. PubMed ID: 10912948
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM;
J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430
[TBL] [Abstract][Full Text] [Related]
8. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
9. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X
Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Shin SJ; Kim H; Baek JH; Ahn JJ; Jegal Y; Seo KW; Park CR; Shin JK; Jung JP; Kim JW; Cha HJ; Kwon WJ; Jeong AK; Noh YJ; Park JH; Min YJ
Lung Cancer; 2008 Apr; 60(1):83-91. PubMed ID: 18006180
[TBL] [Abstract][Full Text] [Related]
12. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Lin CC; Hsu CH; Huang CY; Keng HY; Tsai YC; Huang KH; Cheng AL; Pu YS
Anticancer Drugs; 2007 Apr; 18(4):487-91. PubMed ID: 17351402
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
15. A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Kontopodis E; Kotsakis A; Kentepozidis N; Syrigos K; Ziras N; Moutsos M; Filippa G; Mala A; Vamvakas L; Mavroudis D; Georgoulias V; Agelaki S
Cancer Chemother Pharmacol; 2016 May; 77(5):949-56. PubMed ID: 26994909
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
17. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
[TBL] [Abstract][Full Text] [Related]
19. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
